Managers / Q1 2022 · view latest →
Octagon Capital Advisors LP
CIK 0001839435 · 654 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10065 · 212-369-2829
Summary
Octagon Capital Advisors LP reported $463M in U.S.-listed holdings across 24 positions for Q1 2022.
The portfolio is heavily concentrated: APLSUSD alone accounts for 25.7% of reported value.
Compared with Q4 2021, the fund opened 3 new positions and exited 7.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 91.7% · $424M
- ADR · 3.7% · $17M
- Other · 3.5% · $16M
- ETP · 1.1% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| HORIZON THERAPEUTICS PUB L | NEW | +100.0K | 100.0K | +$11M | $11M |
| SURFUSDSURFACE ONCOLOGY INC | NEW | +2.30M | 2.30M | +$7M | $7M |
| SPDR SER TR | NEW | +55.8K | 55.8K | +$5M | $5M |
| CHINOOK THERAPEUTICS INC | ADDED | +856.3K | 1.36M | +$14M | $22M |
| IMVTIMMUNOVANT INC | ADDED | +902.1K | 1.48M | +$3M | $8M |
| CTKBCYTEK BIOSCIENCES INC | SOLD OUT | −400.0K | 0 | −$7M | $0 |
| CRDFCARDIFF ONCOLOGY INC | SOLD OUT | −982.8K | 0 | −$6M | $0 |
| HELIX ACQUISITION CORP | SOLD OUT | −400.0K | 0 | −$4M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $904M | 29 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $824M | 27 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $660M | 27 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $456M | 30 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $517M | 35 | May 16, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $608M | 33 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $643M | 42 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $636M | 47 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $834M | 57 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $625M | 33 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $651M | 40 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $719M | 41 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $695M | 36 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $642M | 32 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $579M | 35 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $375M | 20 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $463M | 24 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $514M | 28 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $406M | 30 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $483M | 34 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $265M | 28 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $288M | 31 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.